InMed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
INM InMed Pharmaceuticals Inc
ORCL Oracle Corp
OPTT Ocean Power Technologies Inc
SPEYF Spey Resources Corp
BCTX Briacell Therapeutics Corp
JAZZ Jazz Pharmaceuticals PLC
KRT Karat Packaging Inc
REMRF Red Moon Resources Inc
ARR ARMOUR Residential REIT Inc
AROW Arrow Financial Corp
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada
Company profile

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

The symbol you entered, IMLFF, changed to INM.

Price
Delayed
$2.80
Day's Change
0.05 (1.82%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.80
Day's Low
2.76
Volume
1,694

Latest Earnings (Q3 ending 03/2021)

Q3
-$0.41
Q3 Consensus estimate
-$0.24

Latest Earnings Estimate Range

Highest
estimate
-$0.24
Mean
estimate
-$0.24
Lowest
estimate
-$0.24

Quarterly Consensus Estimates and Ranges

INM's fiscal year ends in June

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.